Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) Depreciation & Amortization - Total: 2014-2024

Historic Depreciation & Amortization - Total for Amicus Therapeutics (FOLD) over the last 11 years, with Dec 2024 value amounting to $5.0 million.

  • Amicus Therapeutics' Depreciation & Amortization - Total rose 2.27% to $991,000 in Q1 2019 from the same period last year, while for Mar 2019 it was $4.2 million, marking a year-over-year increase of 12.71%. This contributed to the annual value of $5.0 million for FY2024, which is 4.17% up from last year.
  • According to the latest figures from FY2024, Amicus Therapeutics' Depreciation & Amortization - Total is $5.0 million, which was up 4.17% from $4.8 million recorded in FY2023.
  • In the past 5 years, Amicus Therapeutics' Depreciation & Amortization - Total registered a high of $8.4 million during FY2020, and its lowest value of $4.8 million during FY2022.
  • Moreover, its 3-year median value for Depreciation & Amortization - Total was $4.8 million (2023), whereas its average is $4.9 million.
  • Per our database at Business Quant, Amicus Therapeutics' Depreciation & Amortization - Total surged by 86.67% in 2020 and then slumped by 32.14% in 2021.
  • Amicus Therapeutics' Depreciation & Amortization - Total (Yearly) stood at $8.4 million in 2020, then plummeted by 32.14% to $5.7 million in 2021, then declined by 15.79% to $4.8 million in 2022, then remained steady at $4.8 million in 2023, then grew by 4.17% to $5.0 million in 2024.